文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

减低强度单份无关脐血移植联合可选免疫增强治疗非恶性疾病

Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders.
PubMed 文献 · Blood Adv · 2020-01-01

该前瞻性研究纳入44例先天性代谢、免疫或造血异常患儿,采用阿仑单抗、羟基脲、氟达拉滨、美法仑和塞替派组成的减低强度预处理方案联合单份无关脐血移植,并保留5%移植物用于移植后脐血供者淋巴细胞输注。全部患者均植入,中位植入时间15天,1年时多数患者供者嵌合>90%,仅1例继发性植入失败。II至IV级GVHD发生率为27%(95%CI 17-43),无广泛性慢性GVHD。移植后1年和5年总生存率分别为95%(95%CI 83-99)和85%(95%CI 64-93),未观察到显著终末器官毒性。

要点

  • 44例先天性非恶性疾病患儿接受减低强度预处理联合单份无关脐血移植,全部植入,中位植入时间15天。
  • 移植后1年多数患者供者嵌合>90%,仅1例继发性植入失败。
  • II至IV级GVHD发生率为27%(95%CI 17-43),无广泛性慢性GVHD;1年和5年总生存率分别为95%(95%CI 83-99)和85%(95%CI 64-93)。

核心结论

  • 该减低强度预处理方案联合单份脐血移植在先天性代谢、免疫或造血异常患儿中取得了优异的生存率和显著低的植入失败率。
  • 作者认为,该方案无需药代动力学监测,在全球范围内对此类患儿可行且适用。

研究设计与样本

  • 前瞻性研究,纳入44例连续先天性代谢、免疫或造血异常患儿。
  • 预处理方案为阿仑单抗、羟基脲、氟达拉滨、美法仑和塞替派组成的减低强度方案,联合单份无关脐血移植。
  • 保留5%脐血移植物重新冻存,用于移植后脐血供者淋巴细胞输注(cDLI)。
  • 试验注册号:NCT01962415。

主要发现

  • 全部患者均植入,中位植入时间为移植后15天。
  • 移植后1年时多数患者供者嵌合>90%,仅1例继发性植入失败。
  • II至IV级GVHD发生率为27%(95%CI 17-43),无广泛性慢性GVHD。
  • 移植后1年总生存率为95%(95%CI 83-99),5年总生存率为85%(95%CI 64-93)。
  • 未观察到显著终末器官毒性;cDLI的使用未影响GVHD,并在感染控制或供者嵌合方面显示出疗效信号。

临床怎么用

  • 作者认为,该无需药代动力学监测的方案在全球范围内对先天性代谢、免疫或造血异常患儿可行且适用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with many inherited nonmalignant disorders can be cured or their condition alleviated by hematopoietic stem cell transplantation (HSCT). Umbilical cord blood (UCB) units are a rapidly available stem cell source and offer great flexibility in HLA matching, allowing nearly uniform access to HSCT. Although reduced-intensity conditioning (RIC) regimens promise decreased treatment-related morbidity and mortality, graft failure and infections have limited their use in chemotherapy-naive patients. We prospectively evaluated a novel RIC regimen of alemtuzumab, hydroxyurea, fludarabine, melphalan, and thiotepa with a single-unit UCB graft in 44 consecutive patients with inborn errors of metabolism, immunity, or hematopoiesis. In addition, 5% of the UCB graft was re-cryopreserved and reserved for cord donor leukocyte infusion (cDLI) posttransplant. All patients engrafted at a median of 15 days posttransplant, and chimerism was >90% donor in the majority of patients at 1-year posttransplant with only 1 secondary graft failure. The incidence of grade II to IV graft-versus-host disease (GVHD) was 27% (95% confidence interval [CI], 17-43) with no extensive chronic GVHD. Overall survival was 95% (95% CI, 83-99) and 85% (95% CI, 64-93) at 1 and 5 years posttransplant, respectively. No significant end-organ toxicities were observed. The use of cDLI did not affect GVHD and showed signals of efficacy for infection control or donor chimerism. This RIC transplant regimen using single-unit UCB graft resulted in outstanding survival and remarkably low rates of graft failure. Implementation of the protocol not requiring pharmacokinetic monitoring would be feasible and applicable worldwide for children with inherited disorders of metabolism, immunity, or hematopoiesis. This trial was registered at www.clinicaltrials.gov as #NCT01962415.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Vander Lugt MT, Chen X, Escolar ML, et al. Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders. Blood Adv. 2020. PMID: 32634238. doi:10.1182/bloodadvances.2020001940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。